StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Buy Rating on Lexicon Pharmaceuticals (LXRX): "significant upside potential exists"
March 12, 2026 12:26 PM
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $6.00 price target on Lexicon Pharmaceuticals (NASDAQ: LXRX)The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
